Essential non-redundant terminal differentiation factor; universal immunohistochemical marker of rhabdomyosarcoma
Gene Structure & Expression
Genomic Organization & Cytogenetic Locus: 3-exon gene on chromosome 1q32.1 whose proximal promoter contains an E-box (bound by upstream MYOD1 and MYF5) paired with a MEF2 binding site, encoding a 224-amino-acid bHLH transcription factor.
Cellular & Tissue Expression Profile: Absent in quiescent satellite cells and proliferating myoblasts, but sharply induced as myoblasts exit the cell cycle to differentiate into multinucleated myotubes; in adult muscle, MYOG is enriched in slow-twitch oxidative type I fibers and is dramatically re-induced upon motor nerve denervation.
Molecular Function & Pathways
Biochemical & Physiological Mechanism: Unlike MYOD1 and MYF5 (which can functionally compensate for each other during initial myoblast specification), MYOG performs an indispensable, non-redundant downstream role: it cooperates with MEF2 transcription factors to activate the fusogenic transmembrane proteins Myomaker (MYMK) and Myomerger (MYMX), sarcomeric myosin heavy chains, troponins, creatine kinase, and acetylcholine receptor subunits.
Clinical & Therapeutic Significance
Human Genetic Variants & Disease Phenotypes: Whereas Myod1-null or Myf5-null mice develop normal skeletal muscle through mutual compensation, Myog-null organisms form normal numbers of committed myoblasts across all muscle beds that completely fail to fuse into contractile myofibers, resulting in perinatal lethality; in denervated adult muscle, loss of electrical activity relieves HDAC4/HDAC5 repression of dachshund/MEF2 to up-regulate MYOG, which drives extra-synaptic nicotinic acetylcholine receptor expression as well as neurogenic atrogenes when denervation is prolonged.
Therapeutic & Clinical Pharmacology: Serves clinically as the gold-standard nuclear immunohistochemical diagnostic marker distinguishing rhabdomyosarcoma (especially alveolar PAX3/7-FOXO1 fusion rhabdomyosarcoma, which shows diffuse >80% nuclear myogenin positivity) from other pediatric small-round-blue-cell tumors.